
Search
Selected Filters
Filter Results
Displaying 21–30 of 356 news results
-
Dec 20, 2024
The company is also planning to conduct the clinical trial at sites in the EU.
-
Dec 16, 2024
The company has also launched a natural history study of patients to inform the planned clinical trial.
-
Dec 13, 2024
Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
Known as ultevursen, the USH2A RNA therapy was licensed from ProQR.
-
Nov 14, 2024
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Nov 13, 2024
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
The companies are planning a Phase 3 clinical trial for the promising gene therapy.
-
Oct 30, 2024
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
The Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
Oct 29, 2024
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
The 36-participant trial will take place at multiple sites in Australia.
-
Oct 23, 2024
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Merger will provide additional capital for gene therapy development.
-
Oct 18, 2024
MicroRNA Breakthroughs: Paving the Way for Vision Restoration
Researchers funded by the Foundation Fighting Blindness are developing microRNA-based therapies for inherited retinal diseases, building on recent Nobel Prize-winning discoveries.
-
Oct 11, 2024
Safety Clinical Trial Launched for Usher Syndrome 3 Drug
Researchers hope the molecule will slow the vision and hearing loss associated with USH3.